Compass Pathways (NASDAQ:CMPS) has announced delays for two key Phase 3 clinical trials involving its psilocybin program, widely seen as a leader in the psychedelic drug development space. As Endpoint News reported, the unexpected timeline shifts, unveiled in the company’s third-quarter earnings report, have led to a 30% reduction in workforce, affecting 55 positions, including some senior management roles. Extended Timelines For Key TrialsCompass originally anticipated releasing data for its COMP005 Phase 3 trial by the fourth quarter of this year; however, this has now been postponed to the …